Facebook link Linked In link You Tube link
  • 2015homepagenew

    FOCIS 2015

    Registration is now open for FOCIS 2015. Learn more.

  • ComputationalSlider

    Computational Immunology

    Don't miss this new educational course at FOCIS 2015! Learn more.

  • rightsize

    FOCIS Education

    FOCIS experts have developed a world class curriculum with options available at events, online, or at your company offices. Learn more.

  • rightsize2

    Strong Collaborations

    In the world of interdisciplinary immunology, collaboration is key. Meet with Key Opinion Leaders and peer from around the world by attending FOCIS 2015.

  • Industry Partnership

    Industry Partnership

    FOCIS provides a plethora of opportunities for industry to interact with immunology experts from around the world. Learn more.

News & Information

FOCIS Center of Excellence Director Leads Project Aimed at Defining a Healthy Immune System

FOCIS Center of Excellence (FCE) Director Matthew Albert, MD, PhD, is coordinating a far-reaching project at the Institut Pasteur in Paris aimed at defining what it means to be “in good health” from a biological standpoint.

The project, known as “Milieu Intérieur” (“Environment Within”), strives to define and increase understanding of what determines a “healthy” individual from the perspective of their immune system by integrating for the first time the relationship between genetics, immunity, and environment.


The Lupus Insight Prize to be Awarded at FOCIS

FOCIS 2015 will once again be hosting the forum for the Lupus Foundation of America, Alliance for Lupus Research and Lupus Research Institute to award the Lupus Insight Prize. The Lupus Insight Prize recipient will be awarded $200,000 to be used for research dedicated to advancing understanding of the genetic, environmental, molecular, immunologic or cellular aspects of lupus and/or its treatment. The Prize must be utilized within three years from the date awarded.


All Articles...




FOCIS ePub Header

September 17, 2014

EditorAndrew H. Lichtman, MD, PhD, Brigham & Women's Hospital
Editorial Board: Abul K. Abbas, MD, University of California, San Francisco | Carla J. Greenbaum, MD, Benaroya Research Institute | Andrew H. Lichtman, MD, PhD, Brigham & Women's Hospital

Highlights from Recent Literature

A Surprising Immune Etiology for Narcolepsy

A review of De la Herrán-Arita, et al., CD4+ T Cell Autoimmunity to Hypocretin/Orexin and Cross-Reactivity to a 2009 H1N1 Influenza A Epitope in Narcolepsy. Science Translational Medicine 5, 216ra176 (2013). PMID: 24353159

Type I narcolepsy is a lifelong disorder characterized by sleepiness, aplexy, and rapid transition from wakefulness to REM sleep. Type I narcolepsy is strongly associated with HLA DQ0602 and results from the loss of the approximately 70,000 posterior hypothalamus neurons that produce the wake promoting neuropeptide hypocretin.


Highlights from Clinical Immunology, Official Journal of FOCIS

A SLAP in the Face of Autoimmunity

A review of Peterson L. et al. SLAP Deficiency Decreases DsDNA Autoantibody Production. Clinical Immunology 150, 201-209, 2014 PMID: 24440645

Src-like adaptor protein (SLAP) down-regulates BCR signaling by promoting c-Cbl-mediated ubiquitin ligation of BCR complex proteins, leading to their degradation. This SLAP function reduces BCR levels in developing B cells. The authors investigated if SLAP deficiency could enhance central B cell tolerance by increasing BCR signaling in developing autoreactive B cells leading to deletion or receptor editing. They tested the effects of SLAP-deficiency using two models of anti-dsDNA autoimmunity. The first model uses vaccination with a peptide mimeotope, which induces an anti-dsDNA response in mice, and glomerular deposition of Ig. The second model is a Ig heavy chain transgenic mouse (56R), in which the transgene was cloned from a B cell derived from autoimmune MRL/lpr mouse. The 56R mouse spontaneously produces anti-dsDNA IgG autoantibodies with various light chains.


Developments in Basic Immunology and Novel Therapies

Old Diseases in a New Bottle: IgG4-related Disease

Shiv Pillai, MD, PhD, Massachusetts General Hospital, Harvard Medical School

Over the past decade a new disease entity has attracted a lot of interest. Patients presenting with tumescent, often painful, lesions affecting a variety of anatomic sites, initially often thought to have a malignant disease, have had biopsies analyzed that reveal a constellation of features that lead to a diagnosis of an entity now called IgG4-related disease or IgG4-RD. The histological features include storiform fibrosis, obliterative phlebitis, and the presence of a lymphoid and plasmacytic cell infiltrate in which forty percent or more of the IgG expressing plasma cells stain for the IgG4 isotype. Plasma levels of IgG4 may also be elevated.


Human Immunophenotyping Update

Data Normalization: How to Handle Batch Effects in Large Studies

Holden T. Maecker, PhD, Stanford University
Janet Siebert, MS, MEd, CytoAnalytics, Inc.

There is a theme among those doing translational immunology that "mice are easy, humans are hard". One of the more subtle ways that this truism plays out is in the greater need to deal with batch effects in human studies. Partly because of genetic heterogeneity, human studies often involve more subjects than a typical animal study. Also, while animal studies can be manipulated so that all the animals reach a particular endpoint at the same time, human studies often cannot. Thus, in situations requiring fresh samples, one must perform the human assays longitudinally. For both of these reasons (number of subjects and the occasional need for real-time assays), one often faces the prospect of comparing human data across multiple "runs" or batches. Given the variability of many immune monitoring assays, this generally results in some run-to-run variability, or "batch effect", and the consequent need for normalization of data across batches (1). Here, we will discuss some high-level considerations that should be given when designing studies for downstream normalization, and what normalization options are available for various study designs.


Selected Recent Clinical Trial Results
  • Systemic Lupus Erythematosus
  • Relapsing-remitting Multiple Sclerosis
  • Crohn's Disease (CD)




Thank you to the 2013 FOCIS Corporate Council:

Amgen 4 Blue      Beckman      CelgeneLogo      genentech color